Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin-like growth factor-1 - Seurat Therapeutics

Next Previous
Drug Profile

Insulin-like growth factor-1 - Seurat Therapeutics

Alternative Names: Insulin-like Growth Factor-1 nasal spray

Latest Information Update: 01 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Chicago
  • Developer Seurat Therapeutics; University of Chicago
  • Class Analgesics; Antimigraines; Growth hormones; Hormonal replacements
  • Mechanism of Action Insulin-like growth factor 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fibromyalgia; Migraine
  • Research Seizures

Most Recent Events

  • 29 Feb 2024 Seurat Therapeutics has patent protection for Insulin-like growth factor-1 for Migraine and related disorders in USA and World (Seurat Therapeutics Website, February 2024)
  • 29 Feb 2024 Seurat Therapeutics has pending patent for Insulin-like growth factor-1 for Migraine and related disorders in USA and World (Seurat Therapeutics Website, February 2024)
  • 29 Feb 2024 Early research in Seizures (Prevention) in USA (Intranasal) (Seurat Therapeutics pipeline; February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top